Cannara Biotech Inc.
LOVE.V
TSX
| 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | 11/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 30.37% | 41.53% | 49.30% | 58.30% | 61.29% |
| Total Other Revenue | -87.92% | -92.40% | -138.78% | -129.78% | -40.50% |
| Total Revenue | 30.53% | 41.73% | 49.15% | 58.25% | 60.61% |
| Cost of Revenue | 54.14% | 71.39% | 79.22% | 70.46% | 71.18% |
| Gross Profit | 2.74% | 8.72% | 16.67% | 43.84% | 49.73% |
| SG&A Expenses | 43.09% | 43.96% | 41.27% | 46.05% | 25.90% |
| Depreciation & Amortization | 15.01% | 41.58% | -16.07% | -21.65% | -20.44% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 49.31% | 61.18% | 63.13% | 57.73% | 49.45% |
| Operating Income | -40.94% | -35.41% | -11.39% | 61.18% | 124.33% |
| Income Before Tax | -41.96% | -37.47% | 6.93% | 74.14% | 204.71% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.60% | -9.91% | 6.93% | 74.14% | 204.71% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.60% | -9.91% | 6.93% | 74.14% | 204.71% |
| EBIT | -40.94% | -35.41% | -11.39% | 61.18% | 124.33% |
| EBITDA | -25.80% | -17.48% | -0.66% | 45.37% | 80.79% |
| EPS Basic | -27.19% | -7.66% | 3.40% | 65.23% | 191.63% |
| Normalized Basic EPS | -67.49% | -70.97% | -41.90% | 60.54% | 195.36% |
| EPS Diluted | -28.12% | -15.43% | -3.49% | 87.88% | 225.74% |
| Normalized Diluted EPS | -68.47% | -72.06% | -41.83% | 60.33% | 196.00% |
| Average Basic Shares Outstanding | -0.50% | 0.25% | 2.39% | 3.44% | 3.17% |
| Average Diluted Shares Outstanding | 0.34% | 1.07% | 2.59% | 3.64% | 3.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |